Additionally, inhibition of ERK1/2 activation downregulated the expressions of Bcl-2 and Bcl-xl [57], and ERK1/2/Bcl-2 signaling is believed to be a potential therapeutic target for cancer cells [58]. This evidence concerns the gene MAPK3 and cancer.